Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Share News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.50
Bid: 12.00
Ask: 17.00
Change: 3.60 (31.58%)
Spread: 5.00 (41.667%)
Open: 12.00
High: 15.00
Low: 11.50
Prev. Close: 15.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Braemar Says Oil Tankers Wanted For Storage

Thu, 23rd Apr 2020 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Thursday and not separately reported by Alliance News:

----------

Braemar Shipping Services PLC - shipbroking - Sees solid demand in Tankers market due to oversupply of crude oil, leading to a high demand for vessels to be used for oil storage. Order book grows to USD52 million at March 31 from USD50 million February 29. Securities division sees high levels of activity due to market volatility. Logistics division, Cory Brothers, sees relatively strong start to the year driven by both tanker customers and UK exports. Remains positive about the medium-term outlook for the global shipping market. Suspends final dividend payment for the year ended February 28.

----------

Studio Retail Group PLC - home shopping - Underlying pretax profit for year to March 27 from continuing operations likely to be towards the middle of market forecasts. Revenue for the full year in core Studio unit was 3% ahead of prior year. Decides against providing financial guidance for financial 2021. Studio unit traded well ahead of the prior year during the lockdown period, seeing particularly strong demand for ranges such as toys, games, electricals, fitness and garden. Taking a prudent approach towards stock intake for the summer period, particularly on clothing, in order to de-risk the business. Small number of employees at Studio unit furloughed. Non-core Education business furloughs majority of staff due to school closures and sees demand plummet at around 20% to 30% of normal levels. Has net debt of GBP53 million and cash on balance sheet of GBP32 million.

----------

Non-Standard Finance PLC - consumer finance - Lending volumes limited to smaller sized loans to key workers only over the past four weeks. Collections performance robust. Everyday Loans collections above 90% of the comparative pre-lockdown levels in March. Guarantor Loans division collections are running at slightly below 90%. Loans at Home unit collections running at 75% of the expected level. Net cash of GBP38.7 million and gross borrowings of GBP345.0 million as of Tuesday. Has access to additional borrowing facilities totalling GBP185 million. Delays release of 2019 to mid-May.

----------

Dods Group PLC - information, events and publishing - Continues to address the challenges of the virus crisis. Furloughs one-third of workforce in the UK, while remaining staff working remotely. Decides against issuing any forward guidance due to current uncertainty. Appoints Simon Bullock as chief financial officer. Bullock - a chartered management accountant - has over 20 years' experience as a financial director and chief financial officer.

----------

Blackstone/GSO Loan Financing Ltd - investment fund - Medium and long term impact of the virus pandemic remains uncertain. In the short-term, ratings agency downgrades and corporate defaults of companies within investment portfolios may lead to temporary cashflow diversion. Revises dividend policy and now targets 2020 annual dividend of between EUR0.06 and EUR0.07 per share, down from EUR0.10. Declares EUR0.015 per share dividend for the quarter to end-March.

----------

Standard Life Investments Property Income Trust Ltd - commercial property investment - Working closely with tenants to understand their needs during the UK lockdown. Portfolio valuation as at March 31 of GBP458.6 million, down 4.9% from December 31. Loan to value of 24.4% based on March 31 valuation. Cash of GBP5.9 million as of Monday plus GBP47 million in credit facility. Received 66% of rents due as of Monday for second quarter. Rent collection for the period to June 30, and potentially thereafter, to be materially hurt by virus crisis which in turn will reduce future dividends. Confirms intention to pay 1.19 pence per share dividend for the quarter ended March 31. Results for 2019 expected to be released during May.

----------

Smartspace Software PLC - space management software - Taking steps to cut costs and preserve cash including a recruitment freeze, curtailment of all discretionary spend, and office closures. Furloughs 11 staff under UK government's Coronavirus Job Retention Scheme. Withdraws financial guidance for the year ending January 31, 2021. Unable to assess virus impact on financial performance. Had cash of GBP1.9 million as of Monday.

----------

US Solar Fund PLC - solar projects investment - Does not expect Covid-19 to materially impact construction timelines or operating cashflows. More than 55% of the acquired portfolio fully operational and construction of the remainder is progressing to the expected timeline. All debt and tax equity financing required for construction and operations of the acquired portfolio in-place. In a strong position to commence the full 5.5% dividend from first quarter of 2021.

----------

Open Orphan PLC - pharmaceutical services - Subsidiary hVIVO starts testing of an anti-viral for treating Covid-19 on behalf Russian client Nearmedic International Ltd. New drug has both potential anti-viral and anti-inflammatory activity and could reduce both virus infectivity and disease severity. hVIVO will be testing its utility against a panel of viruses to include influenza virus, circulating betacoronavirus and SARS-CoV2.

----------

Trifast PLC - industrial fastenings - Revenue for the year ended March 31 held up well against the prior year. Underlying pretax profit broadly in line with market expectations despite reduced trading levels as a result of reduction in manufacturing volumes across end markets. Decides against declaring dividend for financial 2020. Removes earnings guidance for financial 2021. Making full use of available government backed job retention and wage subsidy schemes. Directors to take a 20% reduction in salaries and fees. Implements a recruitment freeze, a pay-rise deferral, reductions in temporary and contractor headcount and a ban on all non-essential travel.

----------

Trans-Siberian Gold PLC - gold producer - Sees no material impact to production from virus crisis. Dollar-denominated revenue from gold sales remains strong in a supportive gold price environment. Operational costs are rouble-denominated and have fallen due to foreign exchange movements. Revenue for quarter ended March 31 declines to USD9.3 million from USD16.2 million a year ago. First quarter refined gold production down 49% to 6,035 ounces. Gold sales decline 51% to 5,837 ounces. Refined silver output down 28% at 22,205 ounces and sales nil versus 36,329 ounces. Reiterates 2020 gold production guidance of between 38,000 and 42,000 ounces.

----------

Gear4Music PLC - musical instruments - Begins financial 2021 with operational challenges relating to Covid-19. High demand encountered since late March. Appropriately configured to achieve long-term profitable growth. Predicts 9% growth in total sales for year that ended March 31 to GBP120.3 million from GBP109.9 million a year ago. Earnings before interest, tax, depreciation and amortisation of not less than GBP7.0 million versus GBP2.3 million. Cash on hand of GBP7 million at March 31.

----------

SDI Group PLC - scientific and technology products - Continues to operate at all eight sites since UK lockdown began on March 23. To meet market profit expectations for the year ending April 30, with sales of around GBP24 million. Withdraws market guidance for the financial 2021. Cuts salaries and fees of directors by 33% for three months. Furloughs 19% of staff. Current cash in excess of GBP4.5 million, unused debt facilities of GBP600,000, and bank debt of GBP8.9 million.

----------

Amryt Pharma PLC - rare disease treatment - Halts further enrolment to global phase 3 clinical study in Epidermolysis Bullosa, a rare genetic condition resulting in easy blistering of the skin and mucous membranes. Shortly after the last patient completes the end of the double-blind treatment period, the study data will be cleaned and the database locked. Top line data from study expected in late third quarter or early fourth quarter of 2020.

----------

Collagen Solutions PLC - biomaterials and regenerative medicines - Revenue for year to March-end expected to fall 3.3% year-on-year to GBP4.0 million. Experienced Covid-19 impact to the business in March which have hurt full year revenue and are expected to continue to damage trading for the near future. Facing challenges from the virus outbreak in production, logistics and customers. Pursuing additional funding sources including various governments' Covid-19 loans and grants. Board and senior executives including chief executive officer taking 25% pay cut for up to six months. Cash balances at March-end of GBP2.1 million.

----------

Synectics PLC - security and surveillance systems - All business units currently operating, but at significantly reduced levels of activity in every sector and geography. Financial guidance for year ending November 30 remains suspended. Withdrawing resolution for final dividend at annual general meeting. Reducing temporarily salaries and fees for the board and senior management team. Utilising the UK government's Job Retention Scheme, with 30% of UK workforce furloughed. Applying for support, as appropriate, from government schemes in the US, Germany and Singapore. Suspending all discretionary spending, recruitment and capital expenditure. Net cash of GBP3.3 million as of Monday, with confirmed loan facilities of GBP5.0 million.

----------

Kavango Resources PLC - explorer of mineral deposits in Botswana - Minimal disruption so far to the company's operations with recent work focused on analysis and modelling of all data collected over the last 18 months. Constructing a 3D underground map of the northern part of the Kalahari Suture zone. Assessing other prospecting licences at Kalahari copper belt. Seeking a joint venture partner for the Ditau project.

----------

Braveheart Investment Group PLC - fund management and investment - Majority owned Pharm 2 Farm Ltd manufacturing medical grade alcohol hand sanitiser gel. To increase production to 2,000 litres per day by the end of May. Investee Kirkstall Ltd working with Animal Free Research UK to implement new and existing techniques to replace the use of animal in trials and research.

----------

Berkeley Energia Ltd - uranium producer - Focusing on progressing the approvals required to commence construction of the Salamanca mine in Spain and bring it into production. Sees 30% year-to-date jump in uranium spot price to USD32.50 per pound amid uncertainty surrounding Covid-19 impact on the nuclear fuel supply chain.

----------

Cadence Minerals PLC - minerals project investor - No effect of virus outbreak on lithium and tin project in Cinovec, Czech Republic. Restrictions on travel and meetings not expected to have any impact for the foreseeable future on the project. European Metals Holdings Ltd investors have approved EUR29.1 million investment in Cinovec project.

----------

Redx Pharma PLC - drug discovery - Halts recruitment to its phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, to prioritise resources for the UK's National Health Service. Majority of operations in the discovery phase, preclinical phase, and in ongoing research collaborations continuing to plan. Continuing long-term funding discussion with US healthcare firm Redmile Group LLC.

----------

Great Western Mining Corp PLC - minerals exploration in US - Introduces cost saving measures, including agreements with directors and staff to defer 30% of their salaries. Remains in a good cash position and looks forward to restarting activities in the US state of Nevada as soon as circumstances permit.

----------

JPMorgan Claverhouse Investment Trust PLC - investment fund - Directors to reduce fees by 20% due to coronavirus events and the recent fall in assets. The reduction will take effect from start of April 2020 and will continue until June-end.

----------

TP Group PLC - secure communication and software systems - Auditors RSM UK Audit LLP unable to meet agreed timetable to formally report 2019 results. Expects substantial growth in both revenue and adjusted operating profit for 2019, with a significant strengthening of the order book. Seeking clarity from RSM with regards to the timetable for publishing results.

----------

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.